Biofrontera Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $46.2M+23.7% YoYTTM through 30 Jun 2026
Net Income -$6.4MTTM through 30 Jun 2026
Free Cash Flow -$7.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 73.7% |
| EBITDA Margin | -13.8% |
| Operating Margin | -27.2% |
| Net Margin | -13.8% |
Returns
-100.5%ROE
-36.9%ROA
Balance Sheet Health
Debt / Equity0.44x
Current Ratio1.52x
Net Debt-$1.8Mnet cash position
Cash & Equivalents$4.7M
Quality Metrics
Altman Z-Score-6.07
Piotroski F-Score2 / 9
FCF Margin-17.2%
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $41.7M
Diluted EPS-$0.43TTMFY2025: $-1.04
Dividend
No dividend
Capital Allocation
R&D Spend$3M
Capex Intensity6,497.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Product Revenues | $41.7M | +11.7% | View detailsExpected to continue growing as the company expands direct sales team effectiveness and pursues label expansions. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.